HBW Insight is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Kratom Group Sharpens Criticism Of 'Opioid' Finding In FDA's Report To DEA

This article was originally published in The Rose Sheet

Executive Summary

American Kratom Association realizes FDA could have significant influence on DEA decision on whether to schedule kratom constituent ingredients as controlled substances. The association and experts on kratom say FDA's, which concluded that mitragynine and 7-hydroxymitragynine are opioids and use of kratom is dangerous, contains numerous inaccuracies and incorrect conclusions.


Related Content

Kratom Industry Offers Own Standards As Another Firm Warned About FDA Rules
Warnings On Kratom Opioid Withdrawal Claims Mark Tip Of FDA Concerns
Failed NDIs, FDA's Opioid Concerns Don't Stop Kratom Supplement Sales
Kratom Group Contests FDA's Opioid Finding, Requests Joint Meeting With NIDA
FDA's Opioid Label For Kratom Called Misbranding By Marketers
Kratom Experts Seek NIDA As Ally To Show Herb's Safety And Benefits
FDA Turns Kratom's Future In US Dietary Supplement Market Into History
DEA Takes Comments On Kratom, But Keeps Eye On Scheduling





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts